TY - JOUR
T1 - The role of rituximab in the treatment of primary central nervous system lymphoma
AU - Van Dijck, Ruben
AU - Doorduijn, Jeanette K.
AU - Bromberg, Jacoline E.C.
N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/4/16
Y1 - 2021/4/16
N2 - Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methotrexate-based chemotherapy, but whether the addition of the monoclonal anti-CD20 antibody rituximab improves survival, as it does in systemic B-cell non-Hodgkin lymphoma, remains disputed. In this review, we reflect on the available evidence of the use of rituximab in PCNSL. Whether rituximab has any beneficial effect remains uncertain.
AB - Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methotrexate-based chemotherapy, but whether the addition of the monoclonal anti-CD20 antibody rituximab improves survival, as it does in systemic B-cell non-Hodgkin lymphoma, remains disputed. In this review, we reflect on the available evidence of the use of rituximab in PCNSL. Whether rituximab has any beneficial effect remains uncertain.
UR - http://www.scopus.com/inward/record.url?scp=85104304088&partnerID=8YFLogxK
U2 - 10.3390/cancers13081920
DO - 10.3390/cancers13081920
M3 - Review article
AN - SCOPUS:85104304088
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 8
M1 - 1920
ER -
